“Cancer is a growing public health problem. It is the second-leading cause of death worldwide and is the leading or second-leading cause of death before age 70 in 112 countries. As the population ages and increases, the number of cancer cases will rise.”
Drug shows promise for starving out cancer cells
“Starving out tumor cells may be a promising therapy for treatment-resistant lung cancer, according to a new study published in Science Advances.”
Assumptions After a Lung Cancer Diagnosis
“After completing treatment for lung cancer and being told that I was in remission in 2020, I thought about how unique the respective journeys of patients with cancer could be. However, having never smoked, a lung cancer diagnosis was an unlikely, but common experience for many of us.”
Miniature ‘tumor farm’ may guide personalized lung cancer therapy
“Researchers developed a miniature “tumor farm” model that uses biopsied tumor cells to enable personalized, 3-D testing of the cells’ response to various lung cancer drugs.”
Reynolds Says Her Husband Benefited From Biomarker Testing
“Des Moines, Iowa — A bill Governor Reynolds has signed into law has connections to her husband’s lung cancer treatment. The law, which will go into effect July 1st, requires insurance plans to cover biomarker testing. The tests of blood or other genetic material helps doctors determine the best course of treatment for diseases like cancer. The governor’s husband, Kevin, was diagnosed with lung cancer last fall and had a biomarker test.”
Former Worker Program New Mexico Screening Expansion
“On June 5 & 6, the Office of Worker Screening and Compensation Programs is hosting two upcoming events to announce the expansion of the Department of Energy (DOE) Former Worker Medical Screening Program (FWP) for former workers at Los Alamos and Sandia National Laboratories. The event will celebrate the introduction of an early lung cancer screening program with low-dose CT scan for high-risk former DOE workers, as well as the increased availability of occupational medical screening evaluations to detect work-related diseases in all DOE former workers.”
UT Medical Center first in the South to use Cytalux, a drug that ‘lights up’ lung cancer cells
“KNOXVILLE, Tenn. — A hospital in East Tennessee is leading the way against one of the most common types of deadly cancer. The University of Tennessee Medical Center said lung cancer claims more lives in the state than any other cancer.”
Positive 5-Year Results for Gefitinib Combo in EGFR-Variant Lung Cancer
“At a median 5-year follow-up, patients with epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer (NSCLC) who added chemotherapy to gefitinib continued to have strong progression-free survival (PFS) and overall survival (OS) compared with those treated with gefitinib alone, according to a research letter published in JAMA Oncology.”
American Lung Association getting Turquoise for Lung Cancer Action Week
“OMAHA – (May 1, 2024) – Next week, the American Lung Association is turning Nebraska turquoise to raise awareness of lung cancer and encourage residents to take action to end the disease. The Lung Association is also celebrating the 10th anniversary of LUNG FORCE, a nationwide movement to end lung cancer.”
Glecirasib may deliver ‘efficacy and tolerability advantages’ for KRAS-mutant lung cancer
“Nearly 50% of patients with pretreated, locally advanced non-small cell lung cancer harboring a KRAS G12C mutation responded to treatment with glecirasib, findings from a phase 2 study conducted in China showed.”
Moffitt Initiates Groundbreaking Clinical Trial with Oncolytic Virus for Non-Small Cell Lung Cancer
“TAMPA, Fla. — Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following initial frontline standard of care immunotherapy that includes an immune checkpoint inhibitor alone or combined with chemotherapy. The innovative trial uses a novel oncolytic virus, MEM-288, in combination with the immune checkpoint inhibitor nivolumab.”
Video:
Exploring Optimal Treatment for Patients With STK-11– and KEAP-1–Mutated Lung Cancer
